Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on February 20, 2008
J Am Soc Nephrol 19: 863-870, 2008
© 2008 American Society of Nephrology
doi: 10.1681/ASN.2007121377

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2007121377v1
19/5/863    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Vanholder, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vanholder, R.

Special Article

A Bench to Bedside View of Uremic Toxins

Raymond Vanholder*, Ulrich Baurmeister{dagger}, Philippe Brunet{ddagger}, Gerald Cohen§, Griet Glorieux*, Joachim Jankowski|| for the European Uremic Toxin Work Group

* Nephrology Section, Department of Internal Medicine, University Hospital, Ghent, Belgium; {dagger} Nephrology and Medical Intensive Care, University Hospital Charité, Campus Virchow-Klinikum, Berlin, Germany; {ddagger} Néphrologie, Hôpital Conception and INSERM U608, Université Aix-Marseille, France; § Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria; and || Charité, Medizinische Klinik IV, Berlin, Germany

Correspondence: Dr. Raymond Vanholder, Nephrology Section, Department of Internal Medicine, OK12, University Hospital, De Pintelaan 185, B9000 Gent, Belgium. Phone: ++3293324525; Fax: ++3293324599; E-mail: raymond.vanholder{at}ugent.be

Reviewing the current picture of uremic toxicity reveals its complexity. Focusing on cardiovascular damage as a model of uremic effects resulting in substantial morbidity and mortality, most molecules with potential to affect the function of a variety of cell types within the vascular system are difficult to remove by dialysis. Examples are the larger middle molecular weight molecules and protein-bound molecules. Recent clinical studies suggest that enhancing the removal of these compounds is beneficial for survival. Future therapeutic options are discussed, including improved removal of toxins and the search for pharmacologic strategies blocking responsible pathophysiologic pathways.







HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP